Position in NSPR
as of Mar 31, 2026
· filed May 5, 2026
Position Value
$3,418
+$3,362 QoQ
Shares Held
2,098
+6456.2% QoQ
Ownership
0.004%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2022
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NSPR Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Mar 31, 2026UBS Group AG holds $5,241,938,219 across 132 Medical Devices names. NSPR ranks #114 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABT |
Abbott Laboratories
|
12,152,765 | $1,247,724,380 | |
| 2 | BSX |
Boston Scientific Corp
|
14,824,662 | $930,247,536 | |
| 3 | MDT |
Medtronic plc
|
6,412,252 | $555,621,633 | |
| 4 | SYK |
Stryker Corp
|
1,646,714 | $541,093,748 | |
| 5 | DXCM |
Dexcom Inc
|
4,349,959 | $273,177,422 | |
| 6 | EW |
Edwards Lifesciences Corp
|
2,561,776 | $205,147,019 | |
| 7 | GEHC |
GE HealthCare Technologies Inc.
|
2,805,315 | $199,682,320 | |
| 8 | PEN |
Penumbra Inc
|
560,335 | $183,997,200 |
All Filings in NSPR
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,418 | 2,098 | Shares | Defined | 2026-05-05 | |
| 2025-12-31 | $56 | 32 | Shares | Defined | 2026-01-29 | |
| 2025-06-30 | $282,928 | 124,638 | Shares | Defined | 2025-08-14 | |
| 2024-09-30 | $6,332 | 2,363 | Shares | Sole | 2024-11-14 | |
| 2023-12-31 | $3,282 | 1,168 | Shares | Sole | 2024-02-09 | |
| 2023-06-30 | $461 | 184 | Shares | Defined | 2023-08-11 | |
| 2023-03-31 | $116 | 103 | Shares | Sole | 2023-05-12 | |
| 2022-12-31 | $982 | 1,143 | Shares | Sole | 2023-02-08 | |
| 2022-09-30 | $9,214 | 6,226 | Shares | Sole | 2022-11-10 | |
| 2022-06-30 | $9,016 | 4,508 | Shares | Sole | 2022-08-10 | |
| 2022-03-31 | $6,985 | 2,183 | Shares | Sole | 2022-05-16 | |
| No filing history on record for this holder in this stock. | ||||||